- Home
- JYNT vs GALT Comparison
JYNT vs GALT Comparison
Compare JYNT & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYNT
- GALT
- Stock Information
- Founded
- JYNT 2010
- GALT 2000
- Country
- JYNT United States
- GALT United States
- Employees
- JYNT N/A
- GALT N/A
- Industry
- JYNT Multi-Sector Companies
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- JYNT Miscellaneous
- GALT Health Care
- Exchange
- JYNT Nasdaq
- GALT Nasdaq
- Market Cap
- JYNT 154.2M
- GALT 147.8M
- IPO Year
- JYNT 2014
- GALT N/A
- Fundamental
- Price
- JYNT $10.30
- GALT $1.04
- Analyst Decision
- JYNT Strong Buy
- GALT Strong Buy
- Analyst Count
- JYNT 2
- GALT 1
- Target Price
- JYNT $17.50
- GALT $11.00
- AVG Volume (30 Days)
- JYNT 37.2K
- GALT 1.1M
- Earning Date
- JYNT 11-07-2024
- GALT 11-13-2024
- Dividend Yield
- JYNT N/A
- GALT N/A
- EPS Growth
- JYNT N/A
- GALT N/A
- EPS
- JYNT N/A
- GALT N/A
- Revenue
- JYNT $120,795,620.00
- GALT N/A
- Revenue This Year
- JYNT $3.28
- GALT N/A
- Revenue Next Year
- JYNT N/A
- GALT N/A
- P/E Ratio
- JYNT N/A
- GALT N/A
- Revenue Growth
- JYNT 5.26
- GALT N/A
- 52 Week Low
- JYNT $8.88
- GALT $0.73
- 52 Week High
- JYNT $17.82
- GALT $4.27
- Technical
- Relative Strength Index (RSI)
- JYNT 33.35
- GALT 20.80
- Support Level
- JYNT $11.31
- GALT $1.80
- Resistance Level
- JYNT $11.20
- GALT $2.36
- Average True Range (ATR)
- JYNT 0.37
- GALT 0.27
- MACD
- JYNT -0.14
- GALT -0.08
- Stochastic Oscillator
- JYNT 15.34
- GALT 15.07
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.